![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
β-Glycosphingolipids have emerged as a family of potential ligands for natural killer T (NKT)- regulatory lymphocytes. This subset of regulatory lymphocytes has been implicated in the regulation of autoimmune processes. The major histocompatibility complex (MHC) Class I-like CD1d glycoprotein is a member of the CD1 family of antigen-presenting molecules and is responsible for selection of NKT cells. β-Glycolipids have been shown to alter immune responses in the opposing settings of autoimmune diseases or cancer. In this review, we discuss the potential use of β-glycoshpingolipids for NKT-based immunotherapy.
Keywords :
| Abbreviations | ||
| NKT | = | (natural killer T-cell) |
| β-GC | = | (β-glucosylceramide) |
| β-GalCer | = | (β-galactosylceramide) |
| α -GalCer | = | (α -galactosylceramide) |
| Abbreviations | ||
| NKT | = | (natural killer T-cell) |
| β-GC | = | (β-glucosylceramide) |
| β-GalCer | = | (β-galactosylceramide) |
| α -GalCer | = | (α -galactosylceramide) |